Abdominal aortic aneurysm (AAA) is an important cause of mortality in the older adults due to aortic rupture. Surgical repair (either by endovascular or open surgery) is the only treatment for AAA, however, large randomized controlled trials suggest that elective repair of small (<55mm) AAAs does not reduce all-cause mortality. Most AAAs detected through screening programs or incidental imaging are too small to warrant immediate surgical repair. Such patients are managed conservatively with repeated imaging to monitor AAA diameter, however, 60-70% of AAAs managed in this way eventually grow to a size warranting elective surgery. Discovery of a drug therapy which effectively slows the growth of small AAAs has significant potential to improve patient welfare and reduce the number of individuals requiring elective surgery. This chapter reviews the current understanding of AAA pathogenesis gained through assessment of rodent models and clinical samples. Previous AAA drug trials are also discussed. Finally, the challenges in developing AAA drugs are outlined.This is the accepted version of a chapter which will appear in the 3 rd edition of Mechanisms in Vascular Disease in AAA-mortality expected from a screening programme including all men aged 64-75 years (24). Following from this, the US Preventative Services taskforce has suggested that screening be restricted to individuals considered to be at high risk (e.g. persons with a history of smoking, and/or family history of AAA), in an attempt to improve cost-effectiveness (26). In contrast, AAA screening in the UK and Sweden is offered to all males in the year of their 65 th birthday, and it has been suggested that this may not be financially viable in the light of falling AAA incidence (27). Final findings from an Australian clinical trial demonstrated that a AAA screening program of all men aged >65 years is unlikely to be effective within Australia ( 28), but there is more support for such a program in New Zealand (29). Of note, Māori people are hospitalised for AAA repair at a significantly earlier age than those of European ancestry (difference of 8 years of age at presentation between these two populations), and Māori women have increased risk of developing AAA than their European counterparts (relative risk 1.56 [95% confidence intervals 1.37-1.79]) (30). Thus, any AAA screening program in New Zealand would need to be tailored in order to appropriately meet the needs of specific high-risk groups.
Risk factors identified from epidemiological studiesThe precise initiating factors for AAA development remain unclear, however, epidemiological studies have consistently associated male sex, old age, Anglo-European race, tobacco smoking, family history and prior diagnosis of atherosclerosis-associated cardiovascular disease with increased risks of being diagnosed with an AAA (12,31). Smoking has been shown to be the strongest This is the accepted version of a chapter which will appear in the 3 rd edition of Mechanisms in Vascular Disease modifiable risk factor for AAA (...